<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136565</url>
  </required_header>
  <id_info>
    <org_study_id>LNH05-1T</org_study_id>
    <secondary_id>Janssen: i061-341-03</secondary_id>
    <secondary_id>Eudract: 2005-001563-66</secondary_id>
    <nct_id>NCT00136565</nct_id>
  </id_info>
  <brief_title>Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and the safety profile and toxicity of
      a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP
      [doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone]) in the treatment of
      previously untreated patients with peripheral T-cell lymphoma (PTCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, open-label, non-randomized, non-competitive clinical study,
      evaluating the efficacy and safety of V-ACVBP chemotherapy in previously untreated patients
      aged from 18 to 65 years with peripheral T-lymphoma.

      It is anticipated that 60 subjects will be enrolled over two years (from June 2005 to May
      2007).

      The duration of the treatment period is approximately 28 weeks and patients are followed
      until death.

      The total duration of the study is expected to be 5 years (from June 2005 to May 2010).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2006</start_date>
  <completion_date type="Actual">April 18, 2011</completion_date>
  <primary_completion_date type="Actual">April 18, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>percentage of patients alive with no event, events being defined as disease progression, institution of a new treatment for the lymphoma, relapse after complete response (CR), or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate unconfirmed (CR+CR uncertain)</measure>
    <time_frame>2 years</time_frame>
    <description>percentage of patients with complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR) rate</measure>
    <time_frame>2 years</time_frame>
    <description>percentage of patients with partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of survival without progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in complete responders (CR + CRu)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SAE</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>1.5 mg/m², D1, D5, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>75 mg/m², D1, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60 mg/m², D1-D5, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1200 mg/m², D1, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <description>2 mg/m², D1, D5, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>10 mg, D1, D5, 4 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated non-cutaneous peripheral T-cell lymphoma, including human T-cell
             lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer
             (NK)-cell lymphoma.

          -  Ages 18 to 65 years.

          -  Life expectancy &gt; 3 months.

          -  Written informed consent.

        Exclusion Criteria:

          -  B-cell lymphoma or other subtype of T-cell lymphoma including anaplastic large cell
             lymphoma AKL(+), lymphoblastic lymphoma and primary cutaneous T-cell lymphoma.

          -  Any previous therapy for lymphoma except for short-term corticosteroids before
             inclusion.

          -  Inability to tolerate the ACVBP regimen according to investigator's judgement.

          -  Positive serology for HIV.

          -  Poor renal function (creatinin &gt; 150 µmol/l within 14 days before enrollment), poor
             liver function (total bilirubin &gt; 30 µmol/l, transaminases &gt; 2.5 upper normal limit
             [UNL] within 14 days before enrollment), unless these abnormalities are related to the
             lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.5 G/l or platelets &lt; 100 G/l
             within 14 days before enrollment, unless these abnormalities are related to the
             lymphoma.

          -  Patient with &gt;= grade 2 peripheral neuropathy non-related to lymphoma.

          -  Any central nervous system (CNS) disease.

          -  CNS or meningeal involvement by the lymphoma.

          -  Any serious active disease or comorbidity according to the investigator's decision.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumours or stage 0 (in situ) cervical carcinoma.

          -  Known hypersensitivity to bortezomib, boron or mannitol.

          -  Contraindication to any cytotoxic drug contained in chemotherapy regimen.

          -  Pregnant or lactating women or women of childbearing potential not willing to use an
             adequate method of birth control (i.e. hormonal contraceptive, intra-uterine device,
             diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of
             study.

          -  Men not agreeing to take adequate contraceptive precautions during the study.

          -  Treatment with investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Coiffier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon, Lyon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Delmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Robert Debré</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'Adulte</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.</citation>
    <PMID>15613697</PMID>
  </reference>
  <reference>
    <citation>O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21.</citation>
    <PMID>15613699</PMID>
  </reference>
  <reference>
    <citation>Orlowski RZ. Proteasome inhibitors in cancer therapy. Methods Mol Biol. 2005;301:339-50. Review.</citation>
    <PMID>15917644</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral T-cell lymphomas</keyword>
  <keyword>bortezomib</keyword>
  <keyword>ACVBP regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

